Differential assay for high-throughput screening of antibacterial compounds.
The previously described Bacillus subtilis reporter strain BAU-102 is capable of detecting cell wall synthesis inhibitors that act at all stages of the cell wall synthesis pathway. In addition, this strain is capable of detecting compounds with hydrophobic/surfactant activity and alternative mechanisms of cell wall disruption. BAU-102 sequesters preformed beta-gal in the periplasm, suggesting leakage of beta-gal as the means by which this assay detects compound activities. A model is proposed according to which beta-gal release by BAU-102 reflects activation of pathways leading to autolysis. The authors also report a simplified high-throughput assay using BAU-102 combined with the fluorogenic substrate N-methylumbelliferyl-beta-D-galactoside as a single reagent. Cell wall inhibitors release beta-gal consistently only after 60 min of incubation, whereas compounds with surfactant activity show an almost immediate release. A high-throughput screen of a 480-compound library of known bioactives yielded 8 compounds that cause beta-gal release. These results validate the BAU-102 assay as an effective tool in antimicrobial drug discovery.
Falk
Shaun P
SP
Department of Pharmacology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53706, USA.
Ulijasz
Andrew T
AT
Weisblum
Bernard
B
D000900:Anti-Bacterial Agents / Q000032:analysis* / Q000494:pharmacology; D001412:Bacillus subtilis / Q000187:drug effects; D001433:Bacteriolysis / Q000187:drug effects; D003902:Detergents / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D017930:Genes, Reporter; D019897:Periplasm / Q000187:drug effects / Q000201:enzymology; D014449:Tyrothricin / Q000494:pharmacology; D014640:Vancomycin / Q000494:pharmacology; D001616:beta-Galactosidase / Q000378:metabolism
D000900:Anti-Bacterial Agents; D003902:Detergents; D014449:Tyrothricin; D014640:Vancomycin; D001616:beta-Galactosidase